Maxim Group analyst Naz Rahman reiterated a Buy rating on Cingulate Inc yesterday and set a price target of $8.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Naz Rahman has given his Buy rating due to a combination of factors that highlight Cingulate Inc.’s promising future. The company has entered into a strategic manufacturing agreement with Bend Bio Sciences, positioning itself to transition effectively into a commercial entity. This partnership ensures that Cingulate will have a reliable supply of its lead product, CTx-1301, which is designed to treat ADHD and has shown potential best-in-class onset and duration.
Cingulate’s recent submission of a New Drug Application (NDA) for CTx-1301 to the FDA is another critical milestone. If accepted, this could lead to approval as early as the third quarter of 2026, paving the way for commercialization. The unique once-daily dosing of CTx-1301, combined with the current stimulant shortages, presents a significant market opportunity. Furthermore, the valuation model, which includes a sales risk adjustment and discount rate, supports a 12-month price target of $8.00, reinforcing the Buy recommendation.
In another report released today, Roth MKM also reiterated a Buy rating on the stock with a $10.00 price target.
CING’s price has also changed slightly for the past six months – from $3.700 to $3.700, which is a 0% increase.